UK Medical Guide Weight loss injections, particularly glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide (Wegovy) and liraglutide (Saxenda), can cause dizziness in some individuals
While efficacy endpoints for weight loss in those trials were modest, the compound exhibited a favorable safety profile, supporting its later GRAS designation for food use
The first thing theyll do is ask you questions to determine if youre a viable candidate
Modest weight loss may be seen within the first few weeks (around 1% of body weight per week in early stages), with more significant results becoming apparent after 2-3 months as doses are titrated up
Mechanism of Action: Epigenetic Remodeling
Empower Pharmacy , for example, has different state availability, and Priority Meds covers a different footprint as well